JP2023537403A5 - - Google Patents
Info
- Publication number
- JP2023537403A5 JP2023537403A5 JP2023509723A JP2023509723A JP2023537403A5 JP 2023537403 A5 JP2023537403 A5 JP 2023537403A5 JP 2023509723 A JP2023509723 A JP 2023509723A JP 2023509723 A JP2023509723 A JP 2023509723A JP 2023537403 A5 JP2023537403 A5 JP 2023537403A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063063826P | 2020-08-10 | 2020-08-10 | |
| US63/063,826 | 2020-08-10 | ||
| US202163148982P | 2021-02-12 | 2021-02-12 | |
| US63/148,982 | 2021-02-12 | ||
| PCT/US2021/045350 WO2022035828A1 (en) | 2020-08-10 | 2021-08-10 | Methods of treating gout |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537403A JP2023537403A (ja) | 2023-08-31 |
| JPWO2022035828A5 JPWO2022035828A5 (https=) | 2024-08-20 |
| JP2023537403A5 true JP2023537403A5 (https=) | 2024-08-20 |
Family
ID=80247297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023509723A Pending JP2023537403A (ja) | 2020-08-10 | 2021-08-10 | 痛風を治療する方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230301999A1 (https=) |
| EP (2) | EP4192581A4 (https=) |
| JP (1) | JP2023537403A (https=) |
| KR (1) | KR20230086660A (https=) |
| CN (1) | CN116261463A (https=) |
| AU (1) | AU2021324665A1 (https=) |
| BR (1) | BR112023002458A2 (https=) |
| CA (1) | CA3189100A1 (https=) |
| IL (1) | IL300536A (https=) |
| MX (1) | MX2023001740A (https=) |
| WO (1) | WO2022035828A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| MX2023001740A (es) * | 2020-08-10 | 2023-04-05 | Horizon Therapeutics Usa Inc | Metodos de tratamiento de la gota. |
| CN120152732A (zh) * | 2022-10-24 | 2025-06-13 | 西湖生物医药科技(上海)有限公司 | 诱导特异性免疫耐受的组合 |
| US12201413B2 (en) | 2023-03-01 | 2025-01-21 | Washington University | Free breathing dynamic contrast enhanced (DCE) liver MR imaging |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6783965B1 (en) | 2000-02-10 | 2004-08-31 | Mountain View Pharmaceuticals, Inc. | Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates |
| ES2245114T3 (es) | 1998-08-06 | 2005-12-16 | Mountain View Pharmaceuticals, Inc. | Conjugados de peg-oxidasa de urato y su uso. |
| JP2002524053A (ja) * | 1998-08-06 | 2002-08-06 | デューク・ユニバーシティー | 尿酸オキシダーゼ |
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| WO2006110761A2 (en) | 2005-04-11 | 2006-10-19 | Savient Pharmaceuticals, Inc. | A variant form of urate oxidase and use thereof |
| CN101622270B (zh) | 2006-04-12 | 2014-01-01 | 萨文特医药公司 | 用阳离子表面活性剂纯化蛋白质的方法 |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| ES2986077T3 (es) * | 2016-03-11 | 2024-11-08 | Cartesian Therapeutics Inc | Formulaciones y dosis de uricasa pegilada |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| US20200237881A1 (en) * | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| WO2018169811A1 (en) * | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| WO2020160324A1 (en) * | 2019-01-30 | 2020-08-06 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| MX2023001740A (es) * | 2020-08-10 | 2023-04-05 | Horizon Therapeutics Usa Inc | Metodos de tratamiento de la gota. |
-
2021
- 2021-08-10 MX MX2023001740A patent/MX2023001740A/es unknown
- 2021-08-10 US US18/020,761 patent/US20230301999A1/en active Pending
- 2021-08-10 WO PCT/US2021/045350 patent/WO2022035828A1/en not_active Ceased
- 2021-08-10 EP EP21856554.7A patent/EP4192581A4/en not_active Withdrawn
- 2021-08-10 BR BR112023002458A patent/BR112023002458A2/pt unknown
- 2021-08-10 KR KR1020237008344A patent/KR20230086660A/ko active Pending
- 2021-08-10 CN CN202180053221.3A patent/CN116261463A/zh active Pending
- 2021-08-10 EP EP25163173.5A patent/EP4588513A3/en active Pending
- 2021-08-10 IL IL300536A patent/IL300536A/en unknown
- 2021-08-10 JP JP2023509723A patent/JP2023537403A/ja active Pending
- 2021-08-10 AU AU2021324665A patent/AU2021324665A1/en active Pending
- 2021-08-10 CA CA3189100A patent/CA3189100A1/en active Pending
-
2022
- 2022-02-09 US US17/668,015 patent/US20220323445A1/en active Pending